TY - JOUR AU - Dale, D. C. PY - 2002 DA - 2002// TI - Colony-stimulating factors for the management of neutropenia in cancer patients JO - Drugs VL - 62 UR - https://doi.org/10.2165/00003495-200262001-00001 DO - 10.2165/00003495-200262001-00001 ID - Dale2002 ER - TY - JOUR AU - Lyman, G. H. PY - 2006 DA - 2006// TI - Risks and consequences of chemotherapy-induced neutropenia JO - Clin Cornerstone VL - 8 UR - https://doi.org/10.1016/S1098-3597(06)80054-2 DO - 10.1016/S1098-3597(06)80054-2 ID - Lyman2006 ER - TY - JOUR AU - Crawford, J. AU - Dale, D. C. AU - Lyman, G. H. PY - 2004 DA - 2004// TI - Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management JO - Cancer VL - 100 UR - https://doi.org/10.1002/cncr.11882 DO - 10.1002/cncr.11882 ID - Crawford2004 ER - TY - JOUR AU - Lyman, G. H. AU - Abella, E. AU - Pettengell, R. PY - 2014 DA - 2014// TI - Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review JO - Crit Rev Oncol Hematol VL - 90 UR - https://doi.org/10.1016/j.critrevonc.2013.12.006 DO - 10.1016/j.critrevonc.2013.12.006 ID - Lyman2014 ER - TY - JOUR AU - Weycker, D. AU - Barron, R. AU - Kartashov, A. AU - Legg, J. AU - Lyman, G. H. PY - 2014 DA - 2014// TI - Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings JO - J Oncol Pharm Pract VL - 20 UR - https://doi.org/10.1177/1078155213492450 DO - 10.1177/1078155213492450 ID - Weycker2014 ER - TY - JOUR AU - Roberts, A. W. PY - 2005 DA - 2005// TI - G-CSF: a key regulator of neutrophil production, but that's not all! JO - Growth Factors VL - 23 UR - https://doi.org/10.1080/08977190500055836 DO - 10.1080/08977190500055836 ID - Roberts2005 ER - TY - JOUR AU - Kuderer, N. M. AU - Dale, D. C. AU - Crawford, J. AU - Lyman, G. H. PY - 2007 DA - 2007// TI - Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review JO - J Clin Oncol VL - 25 UR - https://doi.org/10.1200/JCO.2006.08.8823 DO - 10.1200/JCO.2006.08.8823 ID - Kuderer2007 ER - TY - JOUR AU - Crawford, J. AU - Ozer, H. AU - Stoller, R. AU - Johnson, D. AU - Lyman, G. AU - Tabbara, I. PY - 1991 DA - 1991// TI - Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer JO - N Engl J Med VL - 325 UR - https://doi.org/10.1056/NEJM199107183250305 DO - 10.1056/NEJM199107183250305 ID - Crawford1991 ER - TY - STD TI - Mhaskar R, Clark OAC, Lyman G, Engel Ayer Botrel T, Morganti Paladini L, Djulbegovic B Colony-stimulating factors for chemotherapy-induced febrile neutropenia Cochrane Database Syst Rev 2014;10:CD003039. ID - ref9 ER - TY - JOUR AU - Aapro, M. S. AU - Bohlius, J. AU - Cameron, D. A. AU - Dal, L. L. AU - Donnelly, J. P. AU - Kearney, N. PY - 2011 DA - 2011// TI - 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours JO - Eur J Cancer VL - 47 UR - https://doi.org/10.1016/j.ejca.2010.10.013 DO - 10.1016/j.ejca.2010.10.013 ID - Aapro2011 ER - TY - JOUR AU - Crawford, J. AU - Caserta, C. AU - Roila, F. PY - 2010 DA - 2010// TI - Hematopoietic growth factors: ESMO clinical practice guidelines for the applications JO - Ann Oncol VL - 21 UR - https://doi.org/10.1093/annonc/mdq195 DO - 10.1093/annonc/mdq195 ID - Crawford2010 ER - TY - STD TI - NCCN Clinical Practice Guidelines in Oncology: Myeloid Growth Factors Version 1.2016. ID - ref12 ER - TY - JOUR AU - Smith, T. J. AU - Bohlke, K. AU - Lyman, G. H. AU - Carson, K. R. AU - Crawford, J. AU - Cross, S. J. PY - 2015 DA - 2015// TI - Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2015.62.3488 DO - 10.1200/JCO.2015.62.3488 ID - Smith2015 ER - TY - STD TI - European Medicines Agency, CHMP. Guideline on similar biological medicinal products. Revised overarching guideline on biosimilars, 23 October 2014. ID - ref14 ER - TY - JOUR AU - Aapro, M. AU - Cornes, P. AU - Abraham, I. PY - 2012 DA - 2012// TI - Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia JO - J Oncol Pharm Pract VL - 18 UR - https://doi.org/10.1177/1078155211407367 DO - 10.1177/1078155211407367 ID - Aapro2012 ER - TY - JOUR AU - Sorgel, F. AU - Schwebig, A. AU - Holzmann, J. AU - Prasch, S. AU - Singh, P. AU - Kinzig, M. PY - 2015 DA - 2015// TI - Comparability of biosimilar filgrastim with originator filgrastim: protein characterization, pharmacodynamics, and pharmacokinetics JO - BioDrugs VL - 29 UR - https://doi.org/10.1007/s40259-015-0124-7 DO - 10.1007/s40259-015-0124-7 ID - Sorgel2015 ER - TY - JOUR AU - Gascon, P. AU - Fuhr, U. AU - Sörgel, F. AU - Kinzig-Schippers, M. AU - Makhson, A. AU - Balser, S. PY - 2010 DA - 2010// TI - Development of a new G-CSF product based on biosimilarity assessment JO - Ann Oncol VL - 21 UR - https://doi.org/10.1093/annonc/mdp574 DO - 10.1093/annonc/mdp574 ID - Gascon2010 ER - TY - JOUR AU - Blackwell, K. AU - Semiglazov, V. AU - Krasnozhon, D. AU - Davidenko, I. AU - Nelyubina, L. AU - Nakov, R. PY - 2015 DA - 2015// TI - Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy JO - Ann Oncol VL - 26 UR - https://doi.org/10.1093/annonc/mdv281 DO - 10.1093/annonc/mdv281 ID - Blackwell2015 ER - TY - STD TI - Zarzio® Summary of Product Characteristics. Sandoz, Holzkirchen, Germany. https://www.ema.europa.eu/documents/product-information/zarzio-epar-product-information_en.pdf. Last accessed 28 Oct 2018. UR - https://www.ema.europa.eu/documents/product-information/zarzio-epar-product-information_en.pdf ID - ref19 ER - TY - STD TI - Neupogen® Summary of Product Characteristics. Amgen Europe BV. https://www.medicines.org.uk/emc/product/608/smpc. Last accessed 28 Oct 2018. UR - https://www.medicines.org.uk/emc/product/608/smpc ID - ref20 ER - TY - JOUR AU - Gascon, P. AU - Tesch, H. AU - Verpoort, K. AU - Rosati, M. S. AU - Salesi, N. AU - Agrawal, S. PY - 2013 DA - 2013// TI - Clinical experience with Zarzio® in Europe: what have we learned? JO - Support Care Cancer VL - 21 UR - https://doi.org/10.1007/s00520-013-1911-7 DO - 10.1007/s00520-013-1911-7 ID - Gascon2013 ER - TY - JOUR AU - Nahon, S. AU - Rastkhah, M. AU - Ben, A. M. AU - Soumoudronga, R. F. AU - Gasnereau, I. AU - Labourey, J. L. PY - 2016 DA - 2016// TI - Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study JO - Support Care Cancer VL - 24 UR - https://doi.org/10.1007/s00520-015-2986-0 DO - 10.1007/s00520-015-2986-0 ID - Nahon2016 ER - TY - JOUR AU - Gascon, P. AU - Aapro, M. AU - Ludwig, H. AU - Bokemeyer, C. AU - Boccadoro, M. AU - Turner, M. PY - 2016 DA - 2016// TI - Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study) JO - Support Care Cancer VL - 24 UR - https://doi.org/10.1007/s00520-015-2861-z DO - 10.1007/s00520-015-2861-z ID - Gascon2016 ER - TY - STD TI - US Food and Drug Administration. Approved Drugs - filgrastim-sndz. https://www.drugs.com/history/zarxio.html. Last accessed 25 April 2016. UR - https://www.drugs.com/history/zarxio.html ID - ref24 ER - TY - JOUR AU - Almenar, D. AU - Mayans, J. AU - Juan, O. AU - Garcia, B. J. M. AU - Jalon, L. J. I. AU - Frau, A. PY - 2009 DA - 2009// TI - Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain - results of the LEARN study JO - Eur J Cancer Care VL - 18 UR - https://doi.org/10.1111/j.1365-2354.2008.00959.x DO - 10.1111/j.1365-2354.2008.00959.x ID - Almenar2009 ER - TY - JOUR AU - Falandry, C. AU - Campone, M. AU - Cartron, G. AU - Guerin, D. AU - Freyer, G. PY - 2010 DA - 2010// TI - Trends in G-CSF use in 990 patients after EORTC and ASCO guidelines JO - Eur J Cancer VL - 46 UR - https://doi.org/10.1016/j.ejca.2010.04.031 DO - 10.1016/j.ejca.2010.04.031 ID - Falandry2010 ER - TY - JOUR AU - Verpoort, K. AU - Mohler, T. M. PY - 2012 DA - 2012// TI - A non-interventional study of biosimilar granulocyte colony-stimulating factor as prophylaxis for chemotherapy-induced neutropenia in a community oncology Centre JO - Ther Adv Med Oncol VL - 4 UR - https://doi.org/10.1177/1758834012461330 DO - 10.1177/1758834012461330 ID - Verpoort2012 ER - TY - JOUR AU - Damaj, G. L. AU - Benbrahim, O. AU - Hacini, M. AU - Voronina, I. AU - Benabed, K. AU - Soumoudronga, R. -. F. PY - 2017 DA - 2017// TI - ZOHé: A Prospective Study of the Use of Biosimilar Filgrastim Zarzio in Clinical Practice in Patients Treated With Chemotherapy for Lymphoid Malignancies JO - Clin Lymphoma Myeloma Leuk VL - 17 UR - https://doi.org/10.1016/j.clml.2017.05.002 DO - 10.1016/j.clml.2017.05.002 ID - Damaj2017 ER - TY - JOUR AU - Barni, S. AU - Lorusso, V. AU - Giordano, M. AU - Sogno, G. AU - Gamucci, T. AU - Santoro, A. PY - 2014 DA - 2014// TI - A prospective observational study to evaluate G-CSF usage in patients with solid tumors receiving myelosuppressive chemotherapy in Italian clinical oncology practice JO - Med Oncol VL - 31 UR - https://doi.org/10.1007/s12032-013-0797-z DO - 10.1007/s12032-013-0797-z ID - Barni2014 ER - TY - JOUR AU - Link, H. AU - Nietsch, J. AU - Kerkmann, M. AU - Ortner, P. PY - 2016 DA - 2016// TI - Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy--a representative sample survey in Germany JO - Support Care Cancer VL - 24 UR - https://doi.org/10.1007/s00520-015-2779-5 DO - 10.1007/s00520-015-2779-5 ID - Link2016 ER - TY - JOUR AU - Lyman, G. H. AU - Dale, D. C. AU - Legg, J. C. AU - Abella, E. AU - Morrow, P. K. AU - Whittaker, S. PY - 2015 DA - 2015// TI - Assessing patients' risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk? JO - Cancer Med VL - 4 UR - https://doi.org/10.1002/cam4.454 DO - 10.1002/cam4.454 ID - Lyman2015 ER -